Dr Reddy's Laboratories AI Stock Analysis
Want to see RDY full AI Analyst Report?
Dr Reddy's Laboratories (RDY) AI Stock Analysis
Dr Reddy's Laboratories
(NYSE:RDY)
RDY scores in the upper-mid range primarily due to a strong balance sheet and still-healthy profitability, supported by constructive technical momentum (price above key moving averages with positive MACD). The score is held back by deteriorating cash-flow conversion and a near-term slowdown (TTM revenue decline and margin compression), along with a relatively expensive valuation (P/E ~31 and low dividend yield). Earnings-call commentary is a net positive on margin outlook and product catalysts, but tempered by cost pressures and regulatory/validation uncertainty.
Dr Reddy's Laboratories (RDY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $12.33B
- Dividend Yield
- 0.76%
- Average Volume (3M)
- 2.88M
- Price to Earnings (P/E)
- 41.3
- Beta (1Y)
- 0.29
- Revenue Growth
- -10.52%
- EPS Growth
- -55.45%
- Country
- US
- Employees
- 27,527
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Dr Reddy's Laboratories Business Overview & Revenue Model
Company Description
Established in 1984 and headquartered in Hyderabad, India, Dr. Reddy's Laboratories Limited functions as a fully integrated global pharmaceutical entity. Its business is structured into several core divisions. The Global Generics segment is responsib...
How the Company Makes Money
Dr. Reddy’s makes money primarily by selling pharmaceutical products and related pharmaceutical inputs across multiple geographies. Key revenue streams include: (1) Generic formulations: The company develops or licenses generic versions of branded dr...
Dr Reddy's Laboratories Earnings Call Summary
The call was predominantly positive. Management highlighted double-digit growth in the underlying business, strong emerging-market and India performance, sequential margin expansion, progress in semaglutide validation and launches, biosimilar and complex-generic opportunities, CDMO growth, and a strong net cash position. The main negatives were the 1.5% year-over-year consolidated revenue decline, lower Lenalidomide sales, declines in North America, Europe, and PSAI, higher input and logistics costs, and remaining regulatory and validation uncertainty around key products.
Q2-2027 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects gross margin in the range 50% to 55% and R&D in the range of 7% to 8% in coming quarters; raw-material, solvent and freight pressures are expected to continue for Q3 and Q4. CapEx is expected to be around ₹1.6 thousand crore to ₹1.7 thousand crore versus earlier guidance of around ₹1.8 thousand crore. NRT is expected to grow somewhere between a high single digit to maybe even double digit, Europe is expected to deliver growth but it will not be significant growth this year, and ex-NRT Europe should grow probably single-digit this year. India is expected to stay a high level of double digit and remain higher than market growth. Semaglutide is expected to resume by November 2026 subject to successful validation, with 6 to 7 million devices this year and a 12 to 15 million pens run rate estimate; Brazil is likely in Q4, while smaller markets are expected to launch either in the end of Q3 or at the beginning of Q4. Abatacept has a December 22nd goal date, with ramp up after 6 months, a 15% to 25% fair market share initially for IV, and subcu expected in February 2028. CDMO is expected to reach 2x to 3x of these numbers in the next 3 to 4 years.
Dr Reddy's Laboratories Financial Statement Overview
Summary
Overall fundamentals are solid but recently pressured. Income statement remains healthy (gross margin ~50%, operating margin ~14%) yet shows a clear near-term slowdown with TTM revenue down and margin compression. Balance sheet is a strength with low leverage (~0.19x debt/equity), though ROE has cooled (~9% TTM). The key drag is cash flow quality: weaker operating cash flow vs earnings and low/declining free-cash-flow conversion.
Income Statement
72PositiveBalance Sheet
80PositiveCash Flow
54Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 331.38B | 353.47B | 325.54B | 279.16B | 245.88B | 214.39B |
| Gross Profit | 163.93B | 186.52B | 190.43B | 163.61B | 139.34B | 113.84B |
| EBITDA | 53.96B | 83.29B | 96.67B | 88.42B | 74.43B | 45.08B |
| Net Income | 28.03B | 45.09B | 56.54B | 55.68B | 45.07B | 23.57B |
Balance Sheet | ||||||
| Total Assets | 577.00B | 567.88B | 492.99B | 387.52B | 321.85B | 292.83B |
| Cash, Cash Equivalents and Short-Term Investments | 76.58B | 86.08B | 57.91B | 81.47B | 61.80B | 44.37B |
| Total Debt | 72.60B | 75.81B | 46.77B | 20.02B | 13.47B | 33.84B |
| Total Liabilities | 185.92B | 194.95B | 155.82B | 106.97B | 90.86B | 102.30B |
| Stockholders Equity | 387.87B | 369.60B | 333.39B | 280.55B | 230.99B | 190.53B |
Cash Flow | ||||||
| Free Cash Flow | 12.01B | 32.10B | 12.03B | 18.00B | 40.01B | 9.06B |
| Operating Cash Flow | 30.11B | 56.65B | 46.43B | 45.43B | 58.88B | 28.11B |
| Investing Cash Flow | -31.03B | -70.53B | -58.08B | -40.28B | -41.37B | -26.39B |
| Financing Cash Flow | 3.08B | 13.40B | 18.91B | -3.76B | -26.86B | -2.42B |
Dr Reddy's Laboratories Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RDY, the sentiment is Positive. The current price of 14.98 is above the 20-day moving average (MA) of 14.30, above the 50-day MA of 13.15, and above the 200-day MA of 13.25, indicating a bullish trend. The MACD of 0.50 indicates Positive momentum. The RSI at 69.58 is Neutral, neither overbought nor oversold. The STOCH value of 56.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RDY.
Dr Reddy's Laboratories Risk Analysis
Dr Reddy's Laboratories disclosed 60 risk factors in its most recent earnings report. Dr Reddy's Laboratories reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksDr Reddy's Laboratories Peers Comparison
Overall Rating
ANIP72Outperform
VTRS67Neutral
RDY67Neutral
TEVA65Neutral
AMRX58Neutral
ALVO43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | $1.59B | 13.52 | 20.00% | ― | 25.94% | 203.25% | |
| 67Neutral | $23.44B | -38.69 | -4.24% | 2.35% | 4.80% | 82.97% | |
| 67Neutral | $12.37B | 41.31 | 7.37% | 0.76% | -10.52% | -55.45% | |
| 65Neutral | $49.04B | 100.35 | 9.18% | ― | 2.99% | -28.63% | |
| 58Neutral | $7.36B | 48.70 | 131.71% | ― | 8.88% | 2272.07% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | $1.56B | -5.46 | 97.21% | ― | -14.25% | -417.72% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RDY | Dr. Reddy's Laboratories Ltd | 14.98 | 1.16 | 8.36% | |
| VTRS | Viatris, Inc. | 20.28 | 10.44 | 106.08% | |
| TEVA | Teva Pharmaceutical Industries Limited | 42.23 | 16.23 | 62.42% | |
| ANIP | Ani Pharmaceuticals | 71.47 | -7.05 | -8.98% | |
| AMRX | Amneal Pharma | 21.88 | 10.36 | 90.01% | |
| ALVO | Alvotech | 4.55 | -0.51 | -10.08% |
Dr Reddy's Laboratories Corporate Events
Dr. Reddy’s Reports VAI Classification and Closure of FTO-3 USFDA Inspection
Dr. Reddy’s Laboratories Ltd. is the reporting company in the filing, which concerned its formulations manufacturing facility, FTO-3, in Bachupally, Hyderabad.On November 14, 2026, the company reported that the USFDA had classified the outcome of its...
Dr. Reddy’s Wins Brazilian Authorization for Generic Semaglutide
Dr. Reddy’s Laboratories is a Hyderabad-based global pharmaceutical company producing APIs, generics, branded generics, biosimilars and over-the-counter medicines, with therapeutic focus including diabetology and major markets including India, the Un...
Dr. Reddy’s Allots 591,270 Shares Under Employee Stock Options
Dr. Reddy’s Laboratories is an India-based pharmaceutical company that develops and markets generic medicines, biosimilars and proprietary products across global markets. Its shares are listed in India and the United States through equity and America...
Dr. Reddy’s Files SEC Form 6-K and Publishes Q2 FY27 Earnings Call Transcript
Dr. Reddy’s Laboratories, a Hyderabad-based global generic pharmaceutical manufacturer listed in India and the U.S., continues to operate as a widely held, internationally regulated issuer in the healthcare sector. Its securities trade under the tick...
Dr. Reddy’s Gets Favorable USFDA VAI Status at Srikakulam Plant
Dr. Reddy’s Laboratories has reported the outcome of a U.S. Food & Drug Administration inspection at its FTO-SEZ Process Unit-02 facility in Srikakulam, Andhra Pradesh. The inspection, originally conducted as a Pre-Approval Inspection and Good Manufa...
Dr. Reddy’s Files Unmodified Auditor Review on September 2026 Interim Results
Dr. Reddy’s Laboratories has submitted a Form 6-K to the U.S. Securities and Exchange Commission dated October 24, 2026, furnishing an intimation from October 23, 2026 regarding its unaudited consolidated financial results for the quarter and half ye...
Dr. Reddy’s Files Form 6-K, Publishes Q2 FY27 Earnings Call Recordings
Dr. Reddy’s Laboratories has filed a Form 6-K with the U.S. Securities and Exchange Commission in October 2026, formally furnishing an intimation dated October 24, 2026, signed by Company Secretary K. Randhir Singh. The filing underscores the company...
Dr. Reddy’s Laboratories Files Q2 FY 2027 Unaudited Results with SEC and Indian Exchanges
On October 23, 2026, Dr. Reddy’s Laboratories announced its unaudited financial results for the quarter and half-year ended September 30, 2026, covering both consolidated and standalone performance. The disclosures were prepared under International F...
Dr. Reddy’s Elevates Aurigene CEO Akhil Ravi to Head API and Services
Dr. Reddy’s Laboratories has strengthened its senior leadership structure with a new appointment in its active pharmaceutical ingredients (API) and services division, underlining the strategic importance of CRDMO and CDMO operations to the group’s gr...
Dr. Reddy’s Releases Q2 FY27 Unaudited Results Presentation
Dr. Reddy’s Laboratories Limited is a global pharmaceutical company based in Hyderabad, India, focused on developing, manufacturing and marketing generic and branded formulations, active pharmaceutical ingredients and biosimilars. The company’s share...
Dr. Reddy’s Interim Q2 FY 2026 Results Receive Clean Auditor Review
Dr. Reddy’s Laboratories Limited has filed a Form 6-K containing its unaudited condensed consolidated interim financial statements for the quarter and six‑month period ended September 30, 2026. The statements are prepared in accordance with IAS 34 an...
Dr. Reddy’s Receives USFDA Form 483 After Pre-Approval Inspection at Visakhapatnam Plant
The U.S. Food and Drug Administration completed a pre-approval inspection at Dr. Reddy’s FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, held from October 8 to October 9, 2026. The plant, which supports the company’s regulated-market a...
Dr. Reddy’s Receives Two-Observation USFDA Form 483 After PAI at FTO-11
Dr. Reddy’s Laboratories has disclosed that the U.S. Food and Drug Administration recently conducted a Pre-Approval Inspection at its FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh. The inspection took place from October 5 to October...
Dr. Reddy’s Sets October 23 Date for Q2 FY27 Results and Global Earnings Call
Dr. Reddy’s Laboratories announced on October 7, 2026 that it will release its financial results for the quarter and six months ended September 30, 2026 on Friday, October 23, 2026, following a meeting of its board of directors. The company has sched...
Dr. Reddy’s U.S. Subsidiary Hit with Modest IRS Penalty, Assessed as Non‑Material
On October 3, 2026, Dr. Reddy’s Laboratories Limited disclosed that its U.S. step‑down wholly owned subsidiary, Dr. Reddy’s Laboratories, Inc., received a final transcript from the Internal Revenue Service dated September 25, 2026, which was delivere...
Dr. Reddy’s Schedules October 23 Board Meet, Closes Trading Window Ahead of Q2 Results
Dr. Reddy’s Laboratories has notified stock exchanges that its Board of Directors will meet on October 23, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter ended September 30, 2026. The disclosure,...
Dr. Reddy’s Schedules Nomura-Led Investor Meet in Hyderabad
Dr. Reddy’s Laboratories filed a Form 6-K with the U.S. Securities and Exchange Commission dated September 21, 2026, as part of its ongoing obligations as a foreign private issuer listed on the New York Stock Exchange. The filing, signed by Company S...
Dr. Reddy’s, Takeda Seal Exclusive Deal to Launch First Approved Dengue Vaccine in India’s Private Market
On September 18, 2026, Dr. Reddy’s Laboratories signed an exclusive agreement with Takeda Biopharmaceuticals India to distribute and market Takeda’s dengue vaccine Qdenga in India’s private market. Under the deal, Dr. Reddy’s will handle promotion an...
Dr. Reddy’s Reports FDA Records Assessment at Mexican API Plant Concluding with Two Observations
Dr. Reddy’s Laboratories disclosed that the U.S. Food and Drug Administration completed a records assessment at its API manufacturing facility, Industrias QuÃmicas Falcón de México (Dr. Reddy’s Mexico), in Jiutepec, Morelos, Mexico. The review, condu...
Dr. Reddy’s Issues New ESOP Shares After ADR Option Exercise
On September 10, 2026, Dr. Reddy’s Laboratories allotted 375 fully paid equity shares of Re.1 each to eligible employees following the exercise of stock options under its Employees ADR Stock Option Scheme, 2007. The new issuance marginally increases...
Dr. Reddy’s Schedules September Analyst and Investor Meetings
On September 10, 2026, Dr. Reddy’s Laboratories filed a regulatory update noting its participation in upcoming analyst and institutional investor conferences. The company’s management plans an in-person group meeting with ICICI Securities in Hyderaba...
Dr. Reddy’s Laboratories Allots New Shares Under Employee Stock Option Scheme
On August 26, 2026, Dr. Reddy’s Laboratories informed the BSE, NSE, NYSE and NSE IFSC that it had allotted 4,110 fully paid equity shares of face value Re.1 each to eligible employees exercising options under the Dr. Reddy’s Employees Stock Option Sc...
Dr. Reddy’s Receives USFDA Form 483 for Bachupally Plant After August Inspection
Dr. Reddy’s Laboratories has disclosed that the U.S. Food & Drug Administration completed a good manufacturing practice inspection of its formulations plant FTO-3 in Bachupally, Hyderabad, conducted between August 6 and August 14, 2026. The inspectio...
Dr. Reddy’s Receives VAI Classification as USFDA Closes Inspection of U.K. API Plant
On August 14, 2026, Dr. Reddy’s Laboratories reported that a U.S. Food & Drug Administration good manufacturing practice inspection of its API facility in Mirfield, West Yorkshire, U.K., conducted earlier and first disclosed on September 8, 2025, has...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026
